AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs)^[1].

PD-1 signaling pathway^[1]

NP-12 TFA displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions ^[1].
NP-12 TFA rescues the proliferation in the mouse splenocyte assay system with average EC₅₀ values of 17 nM and 16.6 nM against rmPD-L1 and rmPD-L2 respectively ^[1].
NP-12 TFA is also able to significantly rescue recombinant human PD-L1 and PD-L2 mediated inhibition of in vitro human PBMC proliferation, with average EC₅₀ values of 63.3 nM and 44.1 nM against PD-L1 and PD-L2 respectively ^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

3375.57

C₅H₁₇TFIN₂O₂S₂Si

H-SNTSESFKF(H-SNTSESF)RVTQLAPKAQIKE-NH2

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Sasikumar PG, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091.